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ABSTRACT
Aim: The study aimed to evaluate verbal memory performance in end stage renal disease (ESRD) patients on maintenance 
haemodialysis (HD) and determine the relationship between the socio-demographic, clinical and biochemical characteristics of 
patients with verbal memory performance.
Methods: A cross-sectional study of 91 ESRD patients on HD from December 2012 to May 2013 was conducted in nephrology 
unit, Hospital Sultanah Bahiyah and 3 private dialysis centres in Alor Setar, Kedah during the study period. Verbal memory 
performance and depression were assessed using the Malay version of the Auditory Verbal Learning Test (MVAVLT) and the 
Beck Depression Inventory (BDI) respectively during the first hour of HD procedures.
Results: Older age, male gender and none/primary education were independently associated with worse verbal memory per­
formance. In contrast, longer duration of HD and anti-diabetic treatment were associated with better verbal memory perfor­
mance. Other factors, including depression, were not significantly associated with verbal memory performance.
Conclusion: Anti-diabetic and HD treatment are associated with better cognitive function. Hence, this study suggests the 
importance of good diabetic control and regular maintenance HD to prevent cognitive impairment in ESRD patients.
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INTRODUCTION
It is well-documented that persons with end stage renal disease 
(ESRD) undergoing hemodialysis (HD) are at considerably higher risk 
for cognitive impairment that includes memory disorders, difficulty in 
planning activities, changes in attention, decreased information process­
ing speed, motor disability, or speech deficits". The etiology of cogni­
tive impairment is multifactorial. The chronic and debilitating nature of 
chronic kidney disease (CKD) along with its exhaustive routine treat­
ments may be responsible for these alterations2'. Stroke symptoms are 
common among patients with ESRD and strongly associated with 
impairments in cognition3’. Traditional vascular risk factors include 
hypertension, diabetes mellitus (DM), hypercholesterolemia, cardiovas­
cular disease, and smoking. In fact, metabolic syndrome may emerge 
earlier in the disease course4'. Other nontraditional vascular risk factors 
that have been associated with cognitive impairment include hyperho- 
mocysteinemia, hemostatic abnormalities, hypercoagulability, inflam­
mation, oxidative stress and anemia56'.
Additionally, patients undergoing HD procedure are exposed to 
unique risk factors and several possible mechanisms for cognitive 
impairment and/or structural brain abnormalities had been investigated. 
Magnetic resonance imaging (MRI) studies had demonstrated signifi­
cant correlation of frontal lobe atrophy with the total number o f dialy­
sis-related hypotension episodes", significantly higher microbleeds in 
HD patients compared to the control group*’ and presence o f cerebral 
oedema in the patients following dialysis", which may present as acute
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neurologic symptoms known as dialysis disequilibrium syndrome in 
severe cases10’. In addition to commonly found risk factors, such as older 
age, atherosclerosis, hypertension, and cerebral amyloid angiopathy"’, 
ESRD patients on HD frequently receive systemic anticoagulation 
during the dialysis procedure further increasing the risk of microbleeds. 
Chronic gaseous microembolization originating either from air bubbles 
in the hemodialysis tubes and filter or from the formation of new air 
bubbles as a result o f pressure gradients and turbulent flow in the dialy­
sis tubing or access is known to occur in hemodialysis patients '2’. 
Intradialytic hypertension is a less-recognized cardiovascular complica­
tion of HD13’ which may progress to hypertensive encephalopathy result­
ing in cerebral hypoperfusion.
Notwithstanding the disease processes underlying the ESRD, the 
HD procedure itself may cause further cognitive impairment in ESRD 
patients via repeated hypotensive episodes, rapid changes in blood pres­
sure, microemboli, brain edema and cerebral microbleeds14'. There is 
absence of high-quality data to support these assertions and thus addi­
tional research in this area is warranted. The objective of this study was 
to evaluate socio-demographic, clinical and biochemical factors associ­
ated with verbal memory performance in ESRD patients on maintenance 
HD. Specifically, the study would like to determine whether duration of 
HD would be associated with reduced verbal memory performance. 
Psychiatric illness and CKD put heavy social burden on caregivers in 
developed countries'516’. Identification of risk factors for cognitive 
impairment would help to reduce the already heavy burdened caregivers 
o f regular HD patients.
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Table 1. Verbal memory performance according to character­
istics of subject (n = 91)
Total learning 
(A1-A5) 
Mean (SD), 
P-value
Delayed free 
recall (A7) 
Mean (SD), 
P-value
Recognition
Mean (SD), 
P-value
All subjects 43.37 (10.75) 10.04 (3.41) 15.0" (1.0)d
Age
< 4 5 47.31 (10.57) 11.39(3.21) 14.56(1.18)
> 4 5 40.80(10.15) 9.16(3.27) 14.02(1.98)
P =  0.005- P = 0.002- P = 0.145“
Gender
Male 41.64(10.26) 9.65 (3.43) 14.04 (2.05)
Female 46.03 (11.07) 10.64 (3.33) 14.53 (1.00)
P =  0.056- P = 0.179“ P = 0.184“
Ethnic
Malay 43.24(10.67) 10.03 (3.41) 14.21 (1.75)
Non-Malay 47.33 (16.65) 10.67(4.51) 14.67 (0.58)
P =  0.813- P =  0.909- P =  0.818-
Marital status
Single 46.18 (11.75) 11.14(3.39) 14.41 (1.40)
Married 43.03 (9.92) 9.84 (3.41) 14.23 (1.88)
38.25 (13.10) 8.63 (2.88) 13.75 (1.28)
P =  0 .185" P = 0.144" P =  0.655"
Divorced/widower
Education
None/primary 33.32 (8.15) 7.58 (2.36) 13.21 (2.46)
Secondary 44.95 (9.92) 10.36 (3.32) 14.44 (1.53)
Tertiary 49.53 (10.15) 11.76(3.33) 14.71 (0.59)
P <  0.001" P <  0.001" P =  0.011‘
Employment
Employed 46.41 (11.27) 10.84 (3.99) 14.32(2.19)
Unemployed 41.30 (9.95) 9.50 (2.85) 14.17(1.33)
P =  0.025“ P =  0.065- P = 0.670-
Smoking hx
Smoker 43.53 (7.64) 10.18(3.09) 14.53 (0.72)
Non-smoker 43.34(11.38) 10.01 (3.49) 14.16 (1.87)
P =  0.948- P =  0.860- P =  0.430-
Anaemia
Yes 44.00 (9.25) 9.94 (3.05) 14.44(0.98)
No 43.03 (11.54) 10.10(3.61) 14.12 (2.01)
0.948- 0.828- 0.401-
Hypertension
Yes 43.86(10.76) 10.30(3.41) 14.34(1.54)
No 40.17(10.54) 8.33 (2.93) 13.50 (2.58)
0.270- 0.061- 0.115-
D/Mellitus
Yes 38.65 (8.85) 8.45 (3.34) 13.84 (2.44)
No 45.82 (10.89) 10.87 (3.14) 14.43 (1.17)
0.002* 0.001- 0.119-
Depression
Yes 41.71 (6.80) 9.36 (2.81) 15.00c (1.00)"
No 43.82(10.89) 10.21 (3.54) 15.00c (1.00)"
0.007- 0.162- 0.836-
“Independent t test, bOne way anova, 'Median, dInterquartile range
M ETH O D O LO G Y
S u b j e c t
The study was approved by the Research & Ethics Committee,
Universiti Sains Malaysia and Ministry of Health Malaysia. A cross sec­
tional study over a period of a six-month was conducted at Nephrology 
Unit, Hospital Sultanah Bahiyah and 3 private dialysis centres in Kedah, 
Northern Peninsula of Malaysia. All ESRD patients age 18-65 on main­
tenance HD for at least 3 months were identified. Patients who were 
unable to complete the rating scale due to hearing, language and visual 
impairments or acutely ill with acute renal failure were excluded. 
Written informed consent was obtained from all patients after a full 
explanation of the procedures of the study. Ninety one patients with 
were recruited by the end of the study period.
A s s e s s m e n t
The Malay Version of Auditory Verbal Learning Test (MVAVLT) is 
a validated Malay version of the Rey Auditory Verbal Learning Test, 
developed to suit the Malaysian population. It has good validity (factor 
analysis 0.66 to 0.98), test-retest reliability (Pearson correlation 0.24 to 
0.84) and sensitive in discriminating between normal and schizophrenia 
patient171. The researcher read a list of words (List A comprised of 15 
concrete nouns), and participants were asked to recall as many of the 
words as they could, in any order (immediate free recall: Al). This pro­
cedure was repeated four times (A2-A5), so that there were five trials 
total. Total learning (A1-A5) reflects the acquisition phase in the memo­
ry information processing operations. Following the list-learning proce­
dure in Al to A5, participants heard a second list of words (List B com­
prised of another 15 concrete nouns) and subsequently tried to name as 
many of these words as possible (immediate free recall: B). Then, the 
participants were asked to name as many words as possible from the 
first list again (post-interference free recall: A6). Following a delay of 
approximately 20 min during which participants engaged in other 
assessment (e.g., interview for socio-demographic, clinical and other 
rating scales), they were asked to recall words from the first list that was 
read to them (delayed free recall: A7). Participants were not expecting 
this free recall condition, as they were not told that there would be fur­
ther tests with the word lists. Following this, a recognition task was 
given, in which participants had to respond yes or no as to whether a 
word, interspersed among semantically or phonetically related words in 
a third list that comprised of 30 words, had been on the list A (recogni­
tion).
The Beck Depression Inventory (BDI) was designed to assess the 
severity of depression'®’. The BDI is a 21-item self-report rating invento­
ry measuring characteristic symptoms of depression. The 21 items are 
answered on a four-point Likert scale in which 0 represents the absence 
of a problem and 3 represents an extreme problem, with a possible total 
score ranging 0 to 63 (normal score 0-10; mild depression 11-20 ; mod­
erate depression 21-30 .severe depression 31-40 and very severe depres­
sion 41-63). Both MVAVLT and BDI were administered within the first 
hour of HD to ensure good cooperation of the participants and standard­
ization of the timing of assessment. Socio-demographic and clinical data 
was ascertained through the participants interview and medical records.
S t a t i s t i c a l  a n a l y s i s
All data will be collected and analyzed using SPSS Version 20. The 
continuous variables were expressed as mean and standard deviation. 
Median and inter-quartile range were used when they were not normally 
distributed. Independent t-test or ANOVA were used to compare the 
mean between the normally distributed clinical data between groups of 
patients on haemodialysis. P-value of less than 0.05 was taken as signif­
icant at 95% confidence interval for all variables. The associations 
between characteristics of subjects with verbal memory performance 
(total learning A1-A5 scores of MVAVLT) were analyzed using single 
linear regression (SLR) analysis to measure the strength of the relation­
ship and control the potential confounding factors. Variables with 
P-value of less than 0.25 were further analyzed using multiple linear 
regression (MLR).
RESULTS
A total of 91 patients (55 males, 36 females) with median age 45.5 
(IQR = 12.1) were recruited. Majority of the subjects were Malay 
(95.6%), married (67%), unemployed (59.3%) and educated up to sec­
ondary level (60.4%). The mean (SD) for total learning (A1-A5), 
post-interference free recall (A6) and delayed free recall (A7) were 
43.37 (10.75), 10.3 (3.39) and 10.04 (3.41), respectively. Subjects age < 
45 years, received tertiary education, employed, not having diabetes
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Table 2. Simple linear regression analysis to determine factors
associated with total learning (A1-A5) in ESRD patients 
on maintenance HD
b* (Cl 95%) t stat P-value
Socio-Demographic Factors
Age -0.352 (-0.52,-0.19) -4.301 0.001
Gender (male vs. female) 4.391 (-0.12,8.90) 1.935 0.056
Ethnicity -3.009 (-13.97,7.95) -5.450 0.587
Malay 2.047 (-4.24,8.33) 0.647 0.519
Chinese -0.216 (-7.32,-0.66) -0.035 0.972
Indian/Others -5.109 (-9.56,-0.66) -0.236 0.814
Employment
Marital Status
Single 3.149 (-2.12,8.42) 1.188 0.238
Married -0.517 (-2.91,1.87) -0.430 0.669
Divorced/Widower -1.594 (-4.25,1.06) -1.193 0.236
Education
None/primary -12.71 (-17.56,-7.87) -5.211 0.001
Secondary 1.987 (-0.28,4.25) 1.744 0.085
Tertiary 2.52 (0.67,4.37) 2.711 0.008
Smoking
Past 0.192(-5.58,5.97) 0.066 0.948
Current -0.159 (-2.49,2.18) -0.135 0.893
Never 0.102 (-1.87,2.07) 0.103 0.919
Clinical Factors
No of Hospitalization (months) -0.668 (-1.19,0.85) -0.328 0.744
Duration of illness (months) 0.050 (0.01,0.91) 2.438 0.015
Duration o f haemodialysis 0.060 (0.03,0.10) 2.827 0.006
(months)
Systolic (mmHg) -0.007 (-0.12,0.10) -0.126 0.400
Diastolic(mmHg) 0.085 (-0.05,0.22) 1.267 0.209
Interdialytic weight gain (kg) 0.702 (-1.15,2.55) 0.756 0.452
Depressive symptoms -0.087 (-0.38, 0.21) -0.034 0.588
(BDI score)
Medical History
Anaemia -0.967 (-5.68,3.74) -0.408 0.685
Hypertension -3.694 (-10.3,2.91) - L i n 0.270
Diabetes mellitus 7.17(2.67,11.67) 3.165 0.002
Hypercholestrolaemia -1.455 (-5.99,3.08) -0.637 0.526
Stroke 0.378 (-21.21.21.97) 0.035 0.972
Heart Disease -5.689 (-27.25,15.87) -0.524 0.601
Medications
Antihypertensive 0.082 (-5.09,5.26) 0.031 0.975
Anticholesterol 3.745 (-0.72,8.20) 1.666 0.099
Antidiabetic 7.048 (1.92,12.18) 2.729 0.008
Heamoglobin agents -1.212 (-7.12,4.69) -0.408 0.685
Calcium agents -0.095 (-8.54,8.35) -0.022 0.982
Antidiuretic 1.952 (-2.59,6.49) 0.853 0.396
Antiplatelet 2.446 (-4.19,9.07) 0.733 0.466
Biochemical Factors
Sr Creatinine (mmol/L) -0.006 (-0.02,0.01) -1.072 0.287
Blood Urea (mmol/L) -0.121 (-0.64,0.39) -0.465 0.644
Sodium (mmol/L) 0.975 (-0.03,1.98) 1.931 0.057
Phosphate (mmol/L) -0.975 (-3.83,1.88) 0.681 0.498
Haemoglobin (g/dL) -0.833 (-2.11,0.44) -1.303 0.196
Fasting Blood Sugar (mmol/L) -0.004 (-0.44,0.43) -0.021 0.984
Fasting Lipid Profile (mmol/L) -0.619 (-3.26,2.02) -0.466 0.642
Sr Albumin (g/dL) -0.272 (-0.63,0.08) -1.506 0.136
Potassium (mmol/L) 0.603 (-3.18,4.39) 0.317 0.752
“Crude regression coefficient
Table 3. Multiple linear regression analysis to determine fac­
tors associated with total learning (A1-A5) in ESRD 
patients on maintenance HD
b" (95% Cl) P-value
Age -0.255 (-0.43, -0.08) 0.005
Gender (male) -4.403 (0.54, 8.27) 0.026
None/primary education -10.665 (-15.44, -5.89) <0.001
Duration of HD 0.052 (0.01, 0.09) 0.009
Antidiabetic 6.406 (2.00, 10.81) 0.005
Sr creatinine -0.008 (-0.02, 0.01) 0.037
Depressive symptoms -0.077 (-0.38, 0.23) 0.614
"Adjusted regression coefficient, Coefficient of determination (R2) = 0.411
Table 4. Comparison of verbal memory performance in other 
studies using MVAVLT
Subjects (n) Age
Mean
(SD)
Total
learning
Mean
(SD)
Delayed
free
recall
Mean
(SD)
Recognition
Mean
(SD)
Healthy controls 38.2 53.2 11.1 14.3
(n = 15)l’> (9.5) (7.7) (2.5) (0.9)
Postmenopausal 55.3 44.4 9.9 13.6
women on EPT 
(n = 39)20)
(3.1) (1.3) (0.4) (0.3)
ESRD on 45.5* 43.37 10.04 15.0*
maintenance HD 
(n = 91)
(12.1-) (10.75) (3.41) (1.0‘)
Smoking 35.5 42.7 9.4 14.0
schizophrenia 
patients (n = 30)20
(8.0) (11.0) (2.5) (2.0)
Schizophrenia 34.6 35.6 7.4 12.6
patients (10.2) (9.8) (2.7) (2.6)
(n = 114)“>
“Median, Interquartile range,
mellitus and depression, scored significantly higher total learning (P < 
0.05) compared to their counterparts. Additionally, 3 of the characteris­
tics (i.e., age, education and absence of diabetes mellitus) were signifi­
cantly associated with better delayed free recall (A7). However, none of 
the characteristics were significantly associated with recognition, as 
shown in table 1.
The MVAVLT total learning (A1-A5) was regressed onto each of 
socio-demographic, clinical and biochemical variables by using SLR 
analysis, as presented in table 2. Six variables had P < 0.05: age; educa­
tion; duration of illness; duration of HD; diabetes mellitus and receiving 
anti-diabetic treatment. In order to allow for more important variables to 
be included in this analysis, all factors with P < 0.25 were further ana­
lyzed using MLR. Forward multiple linear regression method applied 
model assumptions are fulfilled. There were no interactions amongst 
independent variables and no multi-colinearity detected. A total of 5 fac­
tors were significant and independently associated with verbal memory 
performance, as shown in table 3. Older age, male gender and none/pri- 
mary education were associated with worse verbal memory perfor­
mance. In contrast, longer duration of HD and anti-diabetic treatment 
were associated with better verbal memory performance. Serum creati­
nine (P = 0.037) was considered not significant because the 95% confi­
dence interval include zero19). Other factors such depressive symptoms 
and biochemical parameters were not significantly associated with ver­
bal memory performance.
D IS C U S S IO N
ESRD patients on maintenance HD showed impairment of verbal
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memory performance which includes measures of immediate memory, 
delayed recall and recognition. The first author had conducted studies 
on verbal memory performance in different patient populations using 
the same rating scale, as summarized in table 4. Overall, verbal memory 
performance of the ESRD subjects was better compared to schizophre­
nia patients even though schizophrenia patients were on average 10 
years younger. However, this study subjects performed worse compared 
to postmenopausal women on estrogen-progestin therapy (EPT) or 
healthy controls. This was despite the postmenopausal women were on 
average 10 years older. Nevertheless, the above comparison across dif­
ferent studies does not allow the conclusion that these differences are 
significant since the study settings were different and many potential 
confounders were not controlled.
The findings that older age, male gender and none/primary educa­
tion were independently associated with worse verbal learning perfor­
mance were generally consistent with other studies. The finding that 
anti-diabetic treatment was independently associated with better verbal 
memory performance is consistent with a prospective study of 119 
patients with CKD stage 3-5 (including dialysis) and 54 control patients 
without dialysis but with similar vascular risk profile23’. Linear regres­
sion showed that only 3 factors namely: age, HbAlc, and fibrinogen 
predicted cognitive performance. Other factors such as overt vascular 
diseases (i.e., coronary artery disease, stroke, and peripheral artery dis­
ease), subclinical arteriosclerosis markers (namely carotid intima-media 
thickness and ankle-brachial index), other vascular risk factors (namely 
systolic blood pressure, dyslipidemia, smoking, and body-mass index), 
and mood disturbances (namely depression and anxiety) were not sig­
nificant. These results suggest that disturbed glucose control and inflam­
mation contribute to cognitive impairment in CKD. Advanced glycation 
end products (AGE) have recently been considered to be metabolic 
mediators of diabetes, cardiovascular disease and renal disease. In a 
recent study24*, circulating RAGE is associated with reduced eGFR in 
non-diabetic healthy subjects suggesting the important role in modifying 
renal disease and other vascular risk factors.
HD patients reveal considerable changes of cognitive performance 
across the treatment. HD improves attention and memory performance, 
which subsequently deteriorate in between HD sessions25 26’. However, 
only a minority of patients exhibit significant individual cognitive fluc­
tuations, predominantly showing deterioration after dialysis in attention 
and executive functions27’. In conclusion, longer duration of HD was 
independently associated with better verbal memory performance. It 
suggests HD has an overall long term beneficial effect on cognitive 
function even though various mechanisms had been suggested to cause 
cognitive impairment. Other factors including depressive symptoms, 
which affect almost one-fifth of ESRD patients on HD28’, were not sig­
nificantly associated with cognitive impairment.
The limitation of this study was that the cognitive assessment was 
performed during the first hour of HD procedure. Although, this was 
chosen mainly to standardize, facilitate the assessment process and 
ensure good cooperation from the patients, the best cognitive function 
probably was not achieved until after the completion of the procedure. 
The first hour of HD represents the period of rapid physiological and 
biochemical change in patients undergoing HD. Future study should 
perform multiple assessments and involved a larger sample.
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